England (Commonwealth Union)_ As the regulatory environment for pharmaceuticals in the United States becomes more stringent, the CEO of AstraZeneca has encouraged the United Kingdom to invest in future medications.
As the long-term picture for the healthcare industry looks favorable, CEO Pascal Soriot urged the government to safeguard funding for breakthrough medicines in the forthcoming UK budget. While addressing the media, he said: “Of course, it’s clear the government here in the UK, like in many other countries, has to balance the books. It’s just the same as in a company, you need to keep your eye on the long term… I think the government needs to think of protecting industry.”
Soriot, who has led the pharmaceutical industry for a decade, expressed hopes that the government would create a stable environment from both a financial and tax perspective for foreign companies.
Meanwhile, the US Inflation Reduction Act, which was renounced in August, is anticipated to have a negative impact on large pharmaceutical companies in the United States. According to Soriot, the inflation-busting package is bad news for the industry and the United States would likely introduce less innovative products in the following years due to the Act’s pricing limitations on medicines.
AstraZeneca has announced its 15th consecutive quarter of sales growth, recording $33.1bn (£28.6bn) in revenue, led by its oncology division, whose revenue increased by over a third to $4bn (£3.4bn).
The multinational pharmaceutical company withdrew its application to the FDA for their Coronavirus product due to the declining demand for COVID-19 vaccinations around the globe. On the other hand, Pfizer and Johnson & Johnson are providing excellent service to the United States. However, the business is presently pursuing clearance for its COVID-19 medication, Evushield, in the Chinese market, where it hopes to force its way in. Soriot stated that the company is making good progress with the regulators and that he hopes the firm receives clearance before China reopens and the number of COVID-19 cases increases.
